Balyasny Asset Management LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $3.34 Million - $4.1 Million	14,300 New	14,300 $3.93 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $57 Million - $73.5 Million	312,000 Added 2400.0%	325,000 $65.1 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $2.41 Million - $3.14 Million	13,000 New	13,000 $3.09 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $22.5 Million - $29.5 Million	141,000 Added 145.36%	238,000 $40.4 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $20.8 Million - $25.4 Million	-122,300 Reduced 55.77%	97,000 $18.3 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $17.3 Million - $23.8 Million	134,300 Added 158.0%	219,300 $37.2 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $3.17 Million - $4.39 Million	25,000 Added 41.67%	85,000 $12 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $5.59 Million - $8.04 Million	60,000 New	60,000 $6.53 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $3.73 Million - $6.21 Million	-50,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $3.55 Million - $4.39 Million	50,000 New	50,000 $4.02 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.